
References

1. **Riley TV, Bowman RA, Carroll SM.** 1983. Diarrhoea associated with *Clostridium difficile* in a hospital population. *Med J Aust* **1**: 166-9
2. **Kelly CP, LaMont JT.** 2008. *Clostridium difficile*- more difficult than ever. *N Engl J Med* **359**: 1932-40
3. **Stabler RA, Dawson LF, Valiente E, Cairns MD, Martin MJ, Donahue EH, Riley TV, Songer JG, Kuijper EJ, Dingle KE, Wren BW.** 2012. Macro and micro diversity of *Clostridium difficile* isolates from diverse sources and geographical locations. *PLoS One* **7**: e31559
4. **Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T, Croyle K, Krystofiak S, Patel-Brown S, Pasculle AW, Paterson DL, Saul M, Harrison LH.** 2005. A large outbreak of *Clostridium difficile*-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. *Infect Control Hosp Epidemiol* **26**: 273-80
5. **Thomas C, Stevenson M, Riley TV.** 2003. Antibiotics and hospital-acquired *Clostridium difficile*-associated diarrhoea: a systematic review. *J Antimicrob Chemother* **51**: 1339-50
6. **O'Toole H.** 1935. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, *Bacillus difficilis*. *Am J Dis Child* **49**: 390-402
7. **Valiente E, Dawson LF, Cairns MD, Stabler RA, Wren BW.** 2012. Emergence of new PCR ribotypes from the hypervirulent *Clostridium difficile* 027 lineage. *J Med Microbiol* **61**: 49-56
8. **Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC.** 2005. Toxin production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. *Lancet* **366**: 1079-84

-
9. **Goorhuis A, Van der Kooi T, Vaessen N, Dekker FW, Van den Berg R, Harmanus C, van den Hof S, Notermans DW, Kuijper EJ.** 2007. Spread and epidemiology of *Clostridium difficile* polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. *Clin Infect Dis* **45**: 695-703
 10. **Sebahia M, Wren BW, Mullany P, Fairweather N, Minton NP, Stabler RA, Thomson N, Roberts AP, Cerdeno-Tarraga AM, Wang H, Holden MT, Wright A, Churcher C, Quail MA, Baker S, Bason N, Brooks K, Chillingworth T, Cronin A, Davis P, Dowd L, Fraser A, Feltwell T, Hance Z, Holroyd S, Jagels K, Moule S, Mungall K, Price C, Rabinowitsch E, Sharp S, Simmonds M, Stevens K, Unwin L, Whithead S, Dupuy B, Dougan G, Barrell B, Parkhill J.** 2006. The multidrug-resistant human pathogen *Clostridium difficile* has a highly mobile, mosaic genome. *Nat Genet* **38**: 779-86
 11. **Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebahia M, Quail MA, Rose G, Gerding DN, Gibert M, Popoff MR, Parkhill J, Dougan G, Wren BW.** 2009. Comparative genome and phenotypic analysis of *Clostridium difficile* 027 strains provides insight into the evolution of a hypervirulent bacterium. *Genome Biol* **10**: R102
 12. **Sebahia M, Wren BW, Mullany P, Fairweather NF, Minton N, Stabler R, Thomson NR, Roberts AP, Cerdeno-Tarraga AM, Wang H, Holden MT, Wright A, Churcher C, Quail MA, Baker S, Bason N, Brooks K, Chillingworth T, Cronin A, Davis P, Dowd L, Fraser A, Feltwell T, Hance Z, Holroyd S, Jagels K, Moule S, Mungall K, Price C, Rabinowitsch E, Sharp S, Simmonds M, Stevens K, Unwin L, Whithead S, Dupuy B, Dougan G, Barrell B, Parkhill J.** 2006. The multidrug-resistant human pathogen *Clostridium difficile* has a highly mobile, mosaic genome. *Nat Genet* **38**: 779-86
 13. **He M, Sebahia M, Lawley TD, Stabler RA, Dawson LF, Martin MJ, Holt KE, Seth-Smith HM, Quail MA, Rance R, Brooks K, Churcher C, Harris D, Bentley SD, Burrows C, Clark L, Corton C, Murray V, Rose G, Thurston S, van Tonder A, Walker D, Wren BW, Dougan G, Parkhill J.** 2010. Evolutionary dynamics of *Clostridium difficile* over short and long time scales. *Proc Natl Acad Sci USA* **107**: 7527-32
 14. **Zidaric V, Zemljic M, Janezic S, Kocuvan A, Rupnik M.** 2008. High diversity of *Clostridium difficile* genotypes isolated from a single poultry farm producing replacement laying hens. *Anaerobe* **14**: 325-7
-

-
15. **Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, Simmons RL.** 2002. Fulminant *Clostridium difficile*: an underappreciated and increasing cause of death and complications. *Ann Surg* **235**: 363-72
 16. **O'Connor JR, Johnson S, Gerding DN.** 2009. *Clostridium difficile* infection caused by the epidemic BI/NAP1/027 strain. *Gastroenterology* **136**: 1913-24
 17. **Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS.** 2005. Fluoroquinolone prescribing in the United States: 1995 to 2002. *Am J Med* **118**: 259-68
 18. **Spigaglia P, Carattoli A, Barbanti F, Mastrantonio P.** 2010. Detection of *gyrA* and *gyrB* mutations in *Clostridium difficile* isolates by real-time PCR. *Mol Cell Probes* **24**: 61-7
 19. **Kuijper EJ, Coignard B, Brazier JS, Suetens C, Drudy D, Wiuff C, Pituch H, Reichert P, Schneider F, Widmer AF, Olsen KE, Allerberger F, Notermans DW, Barbut F, Delmee M, Wilcox M, Pearson A, Patel BC, Brown DJ, Frei R, Akerlund T, Poxton IR, Tull P.** 2007. Update of *Clostridium difficile*-associated disease due to PCR ribotype 027 in Europe. *Euro Surveill* **12**: E1-2
 20. **Kuijper EJ, Coignard B, Tull P.** 2006. Emergence of *Clostridium difficile*-associated disease in North America and Europe. *Clin Microbiol Infect* **12** Suppl 6: 2-18
 21. **Barbut F, Petit JC.** 2001. Epidemiology of *Clostridium difficile*-associated infections. *Clin Microbiol Infect* **7**: 405-10
 22. **Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J, Jr.** 1995. *Clostridium difficile*-associated diarrhea and colitis. *Infect Control Hosp Epidemiol* **16**: 459-77
 23. **Poutanen SM, Simor AE.** 2004. *Clostridium difficile*-associated diarrhea in adults. *CMAJ* **171**: 51-8
 24. **Sullivan A, Edlund C, Nord CE.** 2001. Effect of antimicrobial agents on the ecological balance of human microflora. *Lancet Infect Dis* **1**: 101-14
 25. **Williams OM, Spencer RC.** 2009. The management of *Clostridium difficile* infection. *Br Med Bull* **91**: 87-110
-

-
26. **Borriello SP, Barclay FE.** 1986. An *in vitro* model of colonisation resistance to *Clostridium difficile* infection. *J Med Microbiol* **21**: 299-309
 27. **Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB.** 2011. The interplay between microbiome dynamics and pathogen dynamics in a murine model of *Clostridium difficile* Infection. *Gut Microbes* **2**: 145-58
 28. **Hurley BW, Nguyen CC.** 2002. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. *Arch Intern Med* **162**: 2177-84
 29. **Wilcox M, Hoy C.** 2001. Broad-spectrum antibiotics in ORACLE. *Lancet* **358**: 503-4
 30. **Owens RC, Jr., Donskey CJ, Gaynes RP, Loo VG, Muto CA.** 2008. Antimicrobial-associated risk factors for *Clostridium difficile* infection. *Clin Infect Dis* **46** Suppl 1: S19-31
 31. **McCusker ME, Harris AD, Perencevich E, Roghmann MC.** 2003. Fluoroquinolone use and *Clostridium difficile*-associated diarrhea. *Emerg Infect Dis* **9**: 730-3
 32. **Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L.** 2005. Emergence of fluoroquinolones as the predominant risk factor for *Clostridium difficile*-associated diarrhea: a cohort study during an epidemic in Quebec. *Clin Infect Dis* **41**: 1254-60
 33. **Brazier JS, Fitzgerald TC, Hosein I, Cefai C, Looker N, Walker M, Bushell AC, Rooney P.** 1999. Screening for carriage and nosocomial acquisition of *Clostridium difficile* by culture: a study of 284 admissions of elderly patients to six general hospitals in Wales. *J Hosp Infect* **43**: 317-9
 34. **Simor AE, Bradley SF, Strausbaugh LJ, Crossley K, Nicolle LE.** 2002. *Clostridium difficile* in long-term-care facilities for the elderly. *Infect Control Hosp Epidemiol* **23**: 696-703
 35. **McFarland LV, Surawicz CM, Stamm WE.** 1990. Risk factors for *Clostridium difficile* carriage and *C. difficile*-associated diarrhea in a cohort of hospitalized patients. *J Infect Dis* **162**: 678-84
-

-
36. **Southern WN, Rahmani R, Aroniadis O, Khorshidi I, Thanjan A, Ibrahim C, Brandt LJ.** 2010. Postoperative *Clostridium difficile*-associated diarrhea. *Surgery* **148**: 24-30
 37. **Dalton BR, Lye-Maccannell T, Henderson EA, Maccannell DR, Louie TJ.** 2009. Proton pump inhibitors increase significantly the risk of *Clostridium difficile* infection in a low-endemicity, non-outbreak hospital setting. *Aliment Pharmacol Ther* **29**: 626-34
 38. **Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, Talmor D.** 2010. Iatrogenic gastric acid suppression and the risk of nosocomial *Clostridium difficile* infection. *Arch Intern Med* **170**: 784-90
 39. **Gurian L, Ward TT, Katon RM.** 1982. Possible foodborne transmission in a case of pseudomembranous colitis due to *Clostridium difficile*: influence of gastrointestinal secretions on *Clostridium difficile* infection. *Gastroenterology* **83**: 465-9
 40. **Low DO, Mamdani MM, Kopp A, Low DE, Juurlink DN.** 2006. Proton pump inhibitors and hospitalization for *Clostridium difficile*-associated disease: a population-based study. *Clin Infect Dis* **43**: 1272-6
 41. **Marra AR, Edmond MB, Wenzel RP, Bearman GM.** 2007. Hospital-acquired *Clostridium difficile*-associated disease in the intensive care unit setting: epidemiology, clinical course and outcome. *BMC Infect Dis* **7**: 42
 42. **Cunney RJ, Magee C, McNamara E, Smyth EG, Walshe J.** 1998. *Clostridium difficile* colitis associated with chronic renal failure. *Nephrol Dial Transplant* **13**: 2842-6
 43. **Bilgrami S, Feingold JM, Dorsky D, Edwards RL, Bona RD, Khan AM, Rodriguez-Pinero F, Clive J, Tutschka PJ.** 1999. Incidence and outcome of *Clostridium difficile* infection following autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant* **23**: 1039-42
 44. **Anand A, Glatt AE.** 1993. *Clostridium difficile* infection associated with antineoplastic chemotherapy: a review. *Clin Infect Dis* **17**: 109-13
 45. **Issa M, Ananthakrishnan AN, Binion DG.** 2008. *Clostridium difficile* and inflammatory bowel disease. *Inflamm Bowel Dis* **14**: 1432-42
-

-
46. **Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, Emmons J, Bajaj JS, Binion DG.** 2007. Impact of *Clostridium difficile* on inflammatory bowel disease. *Clin Gastroenterol Hepatol* **5**: 345-51
 47. **Bignardi GE.** 1998. Risk factors for *Clostridium difficile* infection. *J Hosp Infect* **40**: 1-15
 48. **Forster AJ, Taljaard M, Oake N, Wilson K, Roth V, van Walraven C.** 2012. The effect of hospital-acquired infection with *Clostridium difficile* on length of stay in hospital. *CMAJ* **184**: 37-42
 49. **Kelly CP, Kyne L.** 2011. The host immune response to *Clostridium difficile*. *J Med Microbiol* **60**: 1070-9
 50. **Giannasca PJ, Zhang ZX, Lei WD, Boden JA, Giel MA, Monath TP, Thomas WD, Jr.** 1999. Serum antitoxin antibodies mediate systemic and mucosal protection from *Clostridium difficile* disease in hamsters. *Infect Immun* **67**: 527-38
 51. **Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D.** 2010. Serum anti-toxin B antibody correlates with protection from recurrent *Clostridium difficile* infection (CDI). *Vaccine* **28**: 965-9
 52. **Viscidi R, Laughon BE, Yolken R, Bo-Linn P, Moench T, Ryder RW, Bartlett JG.** 1983. Serum antibody response to toxins A and B of *Clostridium difficile*. *J Infect Dis* **148**: 93-100
 53. **Kyne L, Warny M, Qamar A, Kelly CP.** 2000. Asymptomatic carriage of *Clostridium difficile* and serum levels of IgG antibody against toxin A. *N Engl J Med* **342**: 390-7
 54. **Kyne L, Warny M, Qamar A, Kelly CP.** 2001. Association between antibody response to toxin A and protection against recurrent *Clostridium difficile* diarrhoea. *Lancet* **357**: 189-93
 55. **Bacon AE, 3rd, Fekety R.** 1994. Immunoglobulin G directed against toxins A and B of *Clostridium difficile* in the general population and patients with antibiotic-associated diarrhea. *Diagn Microbiol Infect Dis* **18**: 205-9
-

-
56. **Rupnik M, Wilcox MH, Gerding DN.** 2009. *Clostridium difficile* infection: new developments in epidemiology and pathogenesis. *Nat Rev Microbiol* **7**: 526-36
57. **Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Jr., Leney M, Sloan S, Hay CA, Ambrosino DM.** 2010. Treatment with monoclonal antibodies against *Clostridium difficile* toxins. *N Engl J Med* **362**: 197-205
58. **Walters BA, Roberts R, Stafford R, Seneviratne E.** 1983. Relapse of antibiotic associated colitis: endogenous persistence of *Clostridium difficile* during vancomycin therapy. *Gut* **24**: 206-12
59. **McFarland LV.** 2005. Alternative treatments for *Clostridium difficile* disease: what really works? *J Med Microbiol* **54**: 101-11
60. **Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC.** 2000. Epidemiology of recurrences or reinfections of *Clostridium difficile*-associated diarrhea. *J Clin Microbiol* **38**: 2386-8
61. **Lawley TD, Clare S, Deakin LJ, Goulding D, Yen JL, Raisen C, Brandt C, Lovell J, Cooke F, Clark TG, Dougan G.** 2010. Use of purified *Clostridium difficile* spores to facilitate evaluation of health care disinfection regimens. *Appl Environ Microbiol* **76**: 6895-900
62. **Wilson KH, Sheagren JN, Freter R.** 1985. Population dynamics of ingested *Clostridium difficile* in the gastrointestinal tract of the Syrian hamster. *J Infect Dis* **151**: 355-61
63. **Sorg JA, Sonenshein AL.** 2008. Bile salts and glycine as cogermnants for *Clostridium difficile* spores. *J Bacteriol* **190**: 2505-12
64. **Borriello SP.** 1998. Pathogenesis of *Clostridium difficile* infection. *J Antimicrob Chemother* **41** Suppl C: 13-9
65. **Waligora AJ, Hennequin C, Mullany P, Bourlioux P, Collignon A, Karjalainen T.** 2001. Characterization of a cell surface protein of *Clostridium difficile* with adhesive properties. *Infect Immun* **69**: 2144-53
-

-
66. **Dailey DC, Kaiser A, Schloemer RH.** 1987. Factors influencing the phagocytosis of *Clostridium difficile* by human polymorphonuclear leukocytes. *Infect Immun* **55**: 1541-6
67. **Voth DE, Ballard JD.** 2005. *Clostridium difficile* toxins: mechanism of action and role in disease. *Clin Microbiol Rev* **18**: 247-63
68. **Borriello SP, Davies HA, Kamiya S, Reed PJ, Seddon S.** 1990. Virulence factors of *Clostridium difficile*. *Rev Infect Dis* **12** Suppl 2: S185-91
69. **Lyerly DM, Saum KE, MacDonald DK, Wilkins TD.** 1985. Effects of *Clostridium difficile* toxins given intragastrically to animals. *Infect Immun* **47**: 349-52
70. **Carter GP, Rood JI, Lyras D.** 2010. The role of toxin A and toxin B in *Clostridium difficile*-associated disease: Past and present perspectives. *Gut Microbes* **1**: 58-64
71. **Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI.** 2009. Toxin B is essential for virulence of *Clostridium difficile*. *Nature* **458**: 1176-9
72. **Jank T, Gieseemann T, Aktories K.** 2007. Rho-glucosylating *Clostridium difficile* toxins A and B: new insights into structure and function. *Glycobiology* **17**: 15R-22
73. **Curry SR, Marsh JW, Muto CA, O'Leary MM, Pasculle AW, Harrison LH.** 2007. *tcdC* genotypes associated with severe TcdC truncation in an epidemic clone and other strains of *Clostridium difficile*. *J Clin Microbiol* **45**: 215-21
74. **Murray R, Boyd D, Levett PN, Mulvey MR, Alfa MJ.** 2009. Truncation in the *tcdC* region of the *Clostridium difficile* PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A. *BMC Infect Dis* **9**: 103
75. **Morgan OW, Rodrigues B, Elston T, Verlander NQ, Brown DF, Brazier J, Reacher M.** 2008. Clinical severity of *Clostridium difficile* PCR ribotype 027: a case-case study. *PLoS One* **3**: e1812
76. **McDonald LC, Killgore GE, Thompson A, Owens RC, Jr., Kazakova SV, Sambol SP, Johnson S, Gerding DN.** 2005. An epidemic, toxin gene-variant strain of *Clostridium difficile*. *N Engl J Med* **353**: 2433-41
-

-
77. **Matamouros S, England P, Dupuy B.** 2007. *Clostridium difficile* toxin expression is inhibited by the novel regulator TcdC. *Mol Microbiol* **64**: 1274-88
78. **von Eichel-Streiber C, Sauerborn M, Kuramitsu HK.** 1992. Evidence for a modular structure of the homologous repetitive C-terminal carbohydrate-binding sites of *Clostridium difficile* toxins and *Streptococcus mutans* glucosyltransferases. *J Bacteriol* **174**: 6707-10
79. **Pothoulakis C, Gilbert RJ, Cladaras C, Castagliuolo I, Semenza G, Hitti Y, Montcrief JS, Linevsky J, Kelly CP, Nikulasson S, Desai HP, Wilkins TD, LaMont JT.** 1996. Rabbit sucrase-isomaltase contains a functional intestinal receptor for *Clostridium difficile* toxin A. *J Clin Invest* **98**: 641-9
80. **Tucker KD, Wilkins TD.** 1991. Toxin A of *Clostridium difficile* binds to the human carbohydrate antigens I, X, and Y. *Infect Immun* **59**: 73-8
81. **Hofmann F, Busch C, Prepens U, Just I, Aktories K.** 1997. Localization of the glucosyltransferase activity of *Clostridium difficile* toxin B to the N-terminal part of the holotoxin. *J Biol Chem* **272**: 11074-8
82. **Pfeifer G, Schirmer J, Leemhuis J, Busch C, Meyer DK, Aktories K, Barth H.** 2003. Cellular uptake of *Clostridium difficile* toxin B. Translocation of the N-terminal catalytic domain into the cytosol of eukaryotic cells. *J Biol Chem* **278**: 44535-41
83. **Poxton IR, McCoubrey J, Blair G.** 2001. The pathogenicity of *Clostridium difficile*. *Clin Microbiol Infect* **7**: 421-7
84. **Sehr P, Joseph G, Genth H, Just I, Pick E, Aktories K.** 1998. Glucosylation and ADP ribosylation of rho proteins: effects on nucleotide binding, GTPase activity, and effector coupling. *Biochemistry* **37**: 5296-304
85. **Jank T, Reinert DJ, Giesemann T, Schulz GE, Aktories K.** 2005. Change of the donor substrate specificity of *Clostridium difficile* toxin B by site-directed mutagenesis. *J Biol Chem* **280**: 37833-8
86. **Jank T, Aktories K.** 2008. Structure and mode of action of clostridial glucosylating toxins: the ABCD model. *Trends Microbiol* **16**: 222-9
-

-
87. **Linevsky JK, Pothoulakis C, Keates S, Warny M, Keates AC, Lamont JT, Kelly CP.** 1997. IL-8 release and neutrophil activation by *Clostridium difficile* toxin-exposed human monocytes. *Am J Physiol* **273**: G1333-40
 88. **Jangi S, Lamont JT.** 2010. Asymptomatic colonization by *Clostridium difficile* in infants: implications for disease in later life. *J Pediatr Gastroenterol Nutr* **51**: 2-7
 89. **Eglow R, Pothoulakis C, Itzkowitz S, Israel EJ, O'Keane CJ, Gong D, Gao N, Xu YL, Walker WA, LaMont JT.** 1992. Diminished *Clostridium difficile* toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. *J Clin Invest* **90**: 822-9
 90. **Verma P, Makharia GK.** 2011. *Clostridium difficile* associated diarrhea: new rules for an old game. *Trop Gastroenterol* **32**: 15-24
 91. **Wolf PL, Kasyan A.** 2005. Images in clinical medicine. Pseudomembranous colitis associated with *Clostridium difficile*. *N Engl J Med* **353**: 2491
 92. **Girotra M, Kumar V, Khan JM, Damisse P, Abraham RR, Aggarwal V, Dutta SK.** 2012. Clinical predictors of fulminant colitis in patients with *Clostridium difficile* infection. *Saudi J Gastroenterol* **18**: 133-9
 93. **Jaber MR, Olafsson S, Fung WL, Reeves ME.** 2008. Clinical review of the management of fulminant *Clostridium difficile* infection. *Am J Gastroenterol* **103**: 3195-203
 94. **Goldenberg SD, Cliff PR, French GL.** 2010. Glutamate dehydrogenase for laboratory diagnosis of *Clostridium difficile* infection. *J Clin Microbiol* **48**: 3050-1
 95. **Wren MW, Sivapalan M, Kinson R, Shetty NR.** 2009. Laboratory diagnosis of *Clostridium difficile* infection. An evaluation of tests for faecal toxin, glutamate dehydrogenase, lactoferrin and toxigenic culture in the diagnostic laboratory. *Br J Biomed Sci* **66**: 1-5
 96. **Kelly CP, Pothoulakis C, LaMont JT.** 1994. *Clostridium difficile* colitis. *N Engl J Med* **330**: 257-62
 97. **Doern GV, Coughlin RT, Wu L.** 1992. Laboratory diagnosis of *Clostridium difficile*-associated gastrointestinal disease: comparison of a monoclonal antibody enzyme
-

-
- immunoassay for toxins A and B with a monoclonal antibody enzyme immunoassay for toxin A only and two cytotoxicity assays. *J Clin Microbiol* **30**: 2042-6
98. **Lawley TD, Clare S, Walker AW, Goulding D, Stabler RA, Croucher N, Mastroeni P, Scott P, Raisen C, Mottram L, Fairweather NF, Wren BW, Parkhill J, Dougan G.** 2009. Antibiotic treatment of *Clostridium difficile* carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. *Infect Immun* **77**: 3661-9
99. **Hedge DD, Strain JD, Heins JR, Farver DK.** 2008. New advances in the treatment of *Clostridium difficile* infection (CDI). *Ther Clin Risk Manag* **4**: 949-64
100. **Metchnikoff E.** 1907. The prolongation of life. Optimistic studies. William Heineman, London, United Kingdom
101. **Eiseman B, Silen W, Bascom GS, Kauvar AJ.** 1958. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. *Surgery* **44**: 854-9
102. **Rager KD, George LW, House JK, DePeters EJ.** 2004. Evaluation of rumen transfaunation after surgical correction of left-sided displacement of the abomasum in cows. *J Am Vet Med Assoc* **225**: 915-20
103. **Bakken JS.** 2009. Fecal bacteriotherapy for recurrent *Clostridium difficile* infection. *Anaerobe* **15**: 285-9
104. **Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly C, Khoruts A, Louie T, Martinelli LP, Moore TA, Russell G, Surawicz C.** 2011. Treating *Clostridium difficile* infection with fecal microbiota transplantation. *Clin Gastroenterol Hepatol* **9**: 1044-9
105. **MacConnachie AA, Fox R, Kennedy DR, Seaton RA.** 2009. Faecal transplant for recurrent *Clostridium difficile*-associated diarrhoea: a UK case series. *QJM* **102**: 781-4
106. **Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B, Shekelle PG.** 2012. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. *JAMA* **307**: 1959-69
107. **Surawicz CM.** 2003. Probiotics, antibiotic-associated diarrhoea and *Clostridium difficile* diarrhoea in humans. *Best Pract Res Clin Gastroenterol* **17**: 775-83
-

-
108. **Lee YK, Puong KY.** 2002. Competition for adhesion between probiotics and human gastrointestinal pathogens in the presence of carbohydrate. *Br J Nutr* **88** Suppl 1: S101-8
 109. **Qamar A, Aboudola S, Warny M, Michetti P, Pothoulakis C, LaMont JT, Kelly CP.** 2001. *Saccharomyces boulardii* stimulates intestinal immunoglobulin A immune response to *Clostridium difficile* toxin A in mice. *Infect Immun* **69**: 2762-5
 110. **Rolfe RD.** 2000. The role of probiotic cultures in the control of gastrointestinal health. *J Nutr* **130**: 396S-402S
 111. **Pothoulakis C, Kelly CP, Joshi MA, Gao N, O'Keane CJ, Castagliuolo I, Lamont JT.** 1993. *Saccharomyces boulardii* inhibits *Clostridium difficile* toxin A binding and enterotoxicity in rat ileum. *Gastroenterology* **104**: 1108-15
 112. **Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C.** 1996. *Saccharomyces boulardii* protease inhibits *Clostridium difficile* toxin A effects in the rat ileum. *Infect Immun* **64**: 5225-32
 113. **Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C.** 1999. *Saccharomyces boulardii* protease inhibits the effects of *Clostridium difficile* toxins A and B in human colonic mucosa. *Infect Immun* **67**: 302-7
 114. **Pochapin M.** 2000. The effect of probiotics on *Clostridium difficile* diarrhea. *Am J Gastroenterol* **95**: S11-3
 115. **Lawrence SJ, Korzenik JR, Mundy LM.** 2005. Probiotics for recurrent *Clostridium difficile* disease. *J Med Microbiol* **54**: 905-6
 116. **Bolton RP, Culshaw MA.** 1986. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to *Clostridium difficile*. *Gut* **27**: 1169-72
 117. **Zar FA, Bakkanagari SR, Moorthi KM, Davis MB.** 2007. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clin Infect Dis* **45**: 302-7
 118. **Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME.** 2012. Treatment failure and recurrence of *Clostridium difficile* infection following
-

-
- treatment with vancomycin or metronidazole: a systematic review of the evidence. *Int J Antimicrob Agents* **40**: 1-8
119. **McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN.** 1999. Recurrent *Clostridium difficile* disease: epidemiology and clinical characteristics. *Infect Control Hosp Epidemiol* **20**: 43-50
120. **Johal SS, Lambert CP, Hammond J, James PD, Borriello SP, Mahida YR.** 2004. Colonic IgA producing cells and macrophages are reduced in recurrent and non-recurrent *Clostridium difficile* associated diarrhoea. *J Clin Pathol* **57**: 973-9
121. **Warny M, Vaerman JP, Avesani V, Delmee M.** 1994. Human antibody response to *Clostridium difficile* toxin A in relation to clinical course of infection. *Infect Immun* **62**: 384-9
122. **Sisto F, Scaltrito MM, Zago M, Bonomi A, Cocce V, Frugoni S.** 2011. Molecular analysis of relapses or reinfections of *Clostridium difficile*-associated diarrhea. *New Microbiol* **34**: 399-402
123. **Oka K, Osaki T, Hanawa T, Kurata S, Okazaki M, Manzoku T, Takahashi M, Tanaka M, Taguchi H, Watanabe T, Inamatsu T, Kamiya S.** 2012. Molecular and microbiological characterization of *Clostridium difficile* isolates from single, relapse, and reinfection cases. *J Clin Microbiol* **50**: 915-21
124. **Health Protection Agency.** 2011 [online]. Voluntary surveillance of *Clostridium difficile* in England, Wales and Northern Ireland, 2011. Available: <http://www.hpa.org.uk/web/HPAweb&Page&HPAwebAutoListName/Page/1179745282413>
125. **Office for National Statistics.** 2011 [online]. Deaths involving *Clostridium difficile*, England and Wales, 1999 to 2010. Available: http://www.google.co.uk/#hl=en&client=psy-ab&q=ONS+death+certificates+Clostridium+difficile+England+Wales+1999+2010&oeq=ONS+death+certificates+Clostridium+difficile+England+and+Wales+1999+2010&gs_l=serp.3...1825.6411.0.6645.13.13.0.0.0.218.1606.2_j10j1.13.0...1.0...1c.nV6cbLAOZ_o&pbx=1&bav=on.2,or.r_gc.r_pw.r_qf.&fp=f9ed1d9b74c502ec&biw=1058&bih=492
126. **Health Protection Agency.** 2012 [online]. Summary points on *Clostridium difficile* infection (CDI). Available: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1278944283388
-

-
127. **Healthcare Commission.** 2006 [online]. Investigation into outbreaks of *Clostridium difficile* at Stoke Mandeville Hospital, Buckinghamshire Hospitals NHS Trust. Available: <http://www.buckinghamshirehospitals.nhs.uk/healthcarecommision/HCC-Investigation-into- the-outbreak-of-Clostridium-Difficile.pdf>
 128. **Healthcare Commission.** 2007 [online]. Investigation into outbreaks of *Clostridium difficile* at Maidstone and Tunbridge Wells NHS Trust. Available: http://news.bbc.co.uk/1/shared/bsp/hi/pdfs/11_10_07maidstone_and_tunbridge_wells_investigation_report_oct_2007.pdf
 129. **Health Protection Agency.** 2010/2011 [online]. *Clostridium difficile* ribotyping network (CDRN) for England and Northern Ireland: 2010/2011 annual report. Available: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317133396963
 130. **Verity P, Wilcox MH, Fawley W, Parnell P.** 2001. Prospective evaluation of environmental contamination by *Clostridium difficile* in isolation side rooms. *J Hosp Infect* **49**: 204-9
 131. **Johnson S, Gerding DN.** 1998. *Clostridium difficile*-associated diarrhea. *Clin Infect Dis* **26**: 1027-34
 132. **Sunenshine RH, McDonald LC.** 2006. *Clostridium difficile*-associated disease: new challenges from an established pathogen. *Cleve Clin J Med* **73**: 187-97
 133. **Arias CA, Murray BE.** 2012. The rise of the *Enterococcus*: beyond vancomycin resistance. *Nat Rev Microbiol* **10**: 266-78
 134. **Foulke GE, Silva J, Jr.** 1989. *Clostridium difficile* in the intensive care unit: management problems and prevention issues. *Crit Care Med* **17**: 822-6
 135. **Chang VT, Nelson K.** 2000. The role of physical proximity in nosocomial diarrhea. *Clin Infect Dis* **31**: 717-22
 136. **McFarland LV.** 2002. What's lurking under the bed? Persistence and predominance of particular *Clostridium difficile* strains in a hospital and the potential role of environmental contamination. *Infect Control Hosp Epidemiol* **23**: 639-40
 137. **Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister AR.** 2012. The epidemiology of community-acquired
-

-
- Clostridium difficile* infection: a population-based study. *Am J Gastroenterol* **107**: 89-95
138. **Hookman P, Barkin JS.** 2009. *Clostridium difficile* associated infection, diarrhea and colitis. *World J Gastroenterol* **15**: 1554-80
139. **Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW, Bergwerff AA, Dekker FW, Kuijper EJ.** 2008. Emergence of *Clostridium difficile* infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. *Clin Infect Dis* **47**: 1162-70
140. **Goorhuis A, Debast SB, van Leengoed LA, Harmanus C, Notermans DW, Bergwerff AA, Kuijper EJ.** 2008. *Clostridium difficile* PCR ribotype 078: an emerging strain in humans and in pigs? *J Clin Microbiol* **46**: 1157
141. **Keel K, Brazier JS, Post KW, Weese S, Songer JG.** 2007. Prevalence of PCR ribotypes among *Clostridium difficile* isolates from pigs, calves, and other species. *J Clin Microbiol* **45**: 1963-4
142. **Wilcox MH, Cunniffe JG, Trundle C, Redpath C.** 1996. Financial burden of hospital-acquired *Clostridium difficile* infection. *J Hosp Infect* **34**: 23-30
143. **Buckley AM, Spencer J, Candlish D, Irvine JJ, Douce GR.** 2011. Infection of hamsters with the UK *Clostridium difficile* ribotype 027 outbreak strain R20291. *J Med Microbiol* **60**: 1174-80
144. **Spencer RC.** 1998. Clinical impact and associated costs of *Clostridium difficile*-associated disease. *J Antimicrob Chemother* **41** Suppl C: 5-12
145. **Department of Health.** 2009 [online]. *Clostridium difficile* infection: how to deal with the problem. Available: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_093218.pdf
146. **Gould CV, McDonald LC.** 2008. Bench-to-bedside review: *Clostridium difficile* colitis. *Crit Care* **12**: 203
147. **Zafar AB, Gaydos LA, Furlong WB, Nguyen MH, Mennonna PA.** 1998. Effectiveness of infection control program in controlling nosocomial *Clostridium difficile*. *Am J Infect Control* **26**: 588-93
-

-
148. **Walker AS, Eyre DW, Wyllie DH, Dingle KE, Harding RM, O'Connor L, Griffiths D, Vaughan A, Finney J, Wilcox MH, Crook DW, Peto TE.** 2012. Characterisation of *Clostridium difficile* hospital ward-based transmission using extensive epidemiological data and molecular typing. *PLoS Med* **9**: e1001172
 149. **Nicholson WL, Munakata N, Horneck G, Melosh HJ, Setlow P.** 2000. Resistance of *Bacillus* endospores to extreme terrestrial and extraterrestrial environments. *Microbiol Mol Biol Rev* **64**: 548-72
 150. **Lawley TD, Croucher NJ, Yu L, Clare S, Sebaihia M, Goulding D, Pickard DJ, Parkhill J, Choudhary J, Dougan G.** 2009. Proteomic and genomic characterization of highly infectious *Clostridium difficile* 630 spores. *J Bacteriol* **191**: 5377-86
 151. **Dawson LF, Valiente E, Donahue EH, Birchenough G, Wren BW.** 2011. Hypervirulent *Clostridium difficile* PCR-ribotypes exhibit resistance to widely used disinfectants. *PLoS One* **6**: e25754
 152. **Gerding DN, Muto CA, Owens RC, Jr.** 2008. Measures to control and prevent *Clostridium difficile* infection. *Clin Infect Dis* **46** Suppl 1: S43-9
 153. **Sobel J.** 2005. Botulism. *Clin Infect Dis* **41**: 1167-73
 154. **Engelkirk PG, Duben-Engelkirk J.** 2010. Major infectious diseases of humans, p 344. In Engelkirk PG, Duben-Engelkirk J (ed), *Burton's microbiology for the health sciences*, 9th ed. Lippincott Williams & Wilkins, Philadelphia, PA
 155. **Shafazand S, Doyle R, Ruoss S, Weinacker A, Raffin TA.** 1999. Inhalational anthrax: epidemiology, diagnosis, and management. *Chest* **116**: 1369-76
 156. **Paidhungat M, Setlow B, Driks A, Setlow P.** 2000. Characterization of spores of *Bacillus subtilis* which lack dipicolinic acid. *J Bacteriol* **182**: 5505-12
 157. **Setlow B, Atluri S, Kitchel R, Koziol-Dube K, Setlow P.** 2006. Role of dipicolinic acid in resistance and stability of spores of *Bacillus subtilis* with or without DNA-protective alpha/beta-type small acid-soluble proteins. *J Bacteriol* **188**: 3740-7
 158. **Young SB, Setlow P.** 2004. Mechanisms of *Bacillus subtilis* spore resistance to and killing by aqueous ozone. *J Appl Microbiol* **96**: 1133-42
-

-
159. **Beaman TC, Gerhardt P.** 1986. Heat resistance of bacterial spores correlated with protoplast dehydration, mineralization, and thermal adaptation. *Appl Environ Microbiol* **52**: 1242-6
 160. **Setlow P.** 1995. Mechanisms for the prevention of damage to DNA in spores of *Bacillus* species. *Annu Rev Microbiol* **49**: 29-54
 161. **Setlow P.** 2007. I will survive: DNA protection in bacterial spores. *Trends Microbiol* **15**: 172-80
 162. **Riesenman PJ, Nicholson WL.** 2000. Role of the spore coat layers in *Bacillus subtilis* spore resistance to hydrogen peroxide, artificial UV-C, UV-B, and solar UV radiation. *Appl Environ Microbiol* **66**: 620-6
 163. **Cowan AE, Olivastro EM, Koppel DE, Loshon CA, Setlow B, Setlow P.** 2004. Lipids in the inner membrane of dormant spores of *Bacillus* species are largely immobile. *Proc Natl Acad Sci USA* **101**: 7733-8
 164. **Pearce SM, Kaethler AH.** 1977. Extent of cross-linking of germ cell wall of a variant of *Bacillus cereus*. *Biochem Biophys Res Commun* **77**: 1251-6
 165. **Setlow P.** 2003. Spore germination. *Curr Opin Microbiol* **6**: 550-6
 166. **Moir A, Smith DA.** 1990. The genetics of bacterial spore germination. *Annu Rev Microbiol* **44**: 531-53
 167. **Driks A.** 1999. *Bacillus subtilis* spore coat. *Microbiol Mol Biol Rev* **63**: 1-20
 168. **Henriques AO, Moran CP, Jr.** 2007. Structure, assembly, and function of the spore surface layers. *Annu Rev Microbiol* **61**: 555-88
 169. **Panessa-Warren BJ, Tortora GT, Warren JB.** 1997. Exosporial membrane plasticity of *Clostridium sporogenes* and *Clostridium difficile*. *Tissue Cell* **29**: 449-61
 170. **Lequette Y, Garenaux E, Tauveron G, Dumez S, Perchat S, Slomianny C, Lereclus D, Guerardel Y, Faille C.** 2011. Role played by exosporium glycoproteins in the surface properties of *Bacillus cereus* spores and in their adhesion to stainless steel. *Appl Environ Microbiol* **77**: 4905-11
-

-
171. **Wolska KI, Grudniak AM, Kraczkiewicz-Dowjat A.** 2007. Genetic and physiological regulation of bacterial endospore development. *Pol J Microbiol* **56**: 11-7
 172. **Errington J.** 2010. From spores to antibiotics via the cell cycle. *Microbiology* **156**: 1-13
 173. **Tovar-Rojo F, Chander M, Setlow B, Setlow P.** 2002. The products of the *spoVA* operon are involved in dipicolinic acid uptake into developing spores of *Bacillus subtilis*. *J Bacteriol* **184**: 584-7
 174. **Moir A.** 2006. How do spores germinate? *J Appl Microbiol* **101**: 526-30
 175. **Errington J.** 2003. Regulation of endospore formation in *Bacillus subtilis*. *Nat Rev Microbiol* **1**: 117-26
 176. **Paredes CJ, Alsaker KV, Papoutsakis ET.** 2005. A comparative genomic view of clostridial sporulation and physiology. *Nat Rev Microbiol* **3**: 969-78
 177. **Underwood S, Guan S, Vijayasubhash V, Baines SD, Graham L, Lewis RJ, Wilcox MH, Stephenson K.** 2009. Characterization of the sporulation initiation pathway of *Clostridium difficile* and its role in toxin production. *J Bacteriol* **191**: 7296-305
 178. **Lewis RJ, Brannigan JA, Muchova K, Barak I, Wilkinson AJ.** 1999. Phosphorylated aspartate in the structure of a response regulator protein. *J Mol Biol* **294**: 9-15
 179. **Greene EA, Spiegelman GB.** 1996. The Spo0A protein of *Bacillus subtilis* inhibits transcription of the *abrB* gene without preventing binding of the polymerase to the promoter. *J Biol Chem* **271**: 11455-61
 180. **Strauch M, Webb V, Spiegelman G, Hoch JA.** 1990. The SpoOA protein of *Bacillus subtilis* is a repressor of the *abrB* gene. *Proc Natl Acad Sci USA* **87**: 1801-5
 181. **Healy J, Weir J, Smith I, Losick R.** 1991. Post-transcriptional control of a sporulation regulatory gene encoding transcription factor sigma H in *Bacillus subtilis*. *Mol Microbiol* **5**: 477-87
-

-
182. **Saujet L, Monot M, Dupuy B, Soutourina O, Martin-Verstraete I.** 2011. The key sigma factor of transition phase, SigH, controls sporulation, metabolism, and virulence factor expression in *Clostridium difficile*. *J Bacteriol* **193**: 3186-96
183. **Chastanet A, Vitkup D, Yuan GC, Norman TM, Liu JS, Losick RM.** 2010. Broadly heterogeneous activation of the master regulator for sporulation in *Bacillus subtilis*. *Proc Natl Acad Sci USA* **107**: 8486-91
184. **Molle V, Fujita M, Jensen ST, Eichenberger P, Gonzalez-Pastor JE, Liu JS, Losick R.** 2003. The Spo0A regulon of *Bacillus subtilis*. *Mol Microbiol* **50**: 1683-701
185. **Fawcett P, Eichenberger P, Losick R, Youngman P.** 2000. The transcriptional profile of early to middle sporulation in *Bacillus subtilis*. *Proc Natl Acad Sci USA* **97**: 8063-8
186. **Heap JT, Pennington OJ, Cartman ST, Carter GP, Minton NP.** 2007. The Clostron: a universal gene knock-out system for the genus *Clostridium*. *J Microbiol Methods* **70**: 452-64
187. **Heap JT, Ehsaan M, Cooksley CM, Ng YK, Cartman ST, Winzer K, Minton NP.** 2012. Integration of DNA into bacterial chromosomes from plasmids without a counter-selection marker. *Nucleic Acids Res* **40**: e59
188. **Carter GP, Lyras D, Poon R, Howarth PM, Rood JI.** 2010. Methods for gene cloning and targeted mutagenesis. *Methods Mol Biol* **646**: 183-201
189. **Zhong J, Karberg M, Lambowitz AM.** 2003. Targeted and random bacterial gene disruption using a group II intron (targetron) vector containing a retrotransposition-activated selectable marker. *Nucleic Acids Res* **31**: 1656-64
190. **Heap JT, Kuehne SA, Ehsaan M, Cartman ST, Cooksley CM, Scott JC, Minton NP.** 2010. The Clostron: Mutagenesis in *Clostridium* refined and streamlined. *J Microbiol Methods* **80**: 49-55
191. **Perkins TT, Kingsley RA, Fookes MC, Gardner PP, James KD, Yu L, Assefa SA, He M, Croucher NJ, Pickard DJ, Maskell DJ, Parkhill J, Choudhary J, Thomson NR, Dougan G.** 2009. A strand-specific RNA-Seq analysis of the transcriptome of the typhoid bacillus *Salmonella typhi*. *PLoS Genet* **5**: e1000569
-

-
192. **Martin J, Zhu W, Passalacqua KD, Bergman N, Borodovsky M.** 2010. *Bacillus anthracis* genome organization in light of whole transcriptome sequencing. *BMC Bioinformatics* **11** Suppl 3: S10
193. **Pellin D, Miotto P, Ambrosi A, Cirillo DM, Di Serio C.** 2012. A genome-wide identification analysis of small regulatory RNAs in *Mycobacterium tuberculosis* by RNA-Seq and conservation analysis. *PLoS One* **7**: e32723
194. **Dong TG, Mekalanos JJ.** 2012. Characterization of the RpoN regulon reveals differential regulation of T6SS and new flagellar operons in *Vibrio cholerae* O37 strain V52. *Nucleic Acids Res* **40**: 7766-75
195. **Purdy D, O'Keeffe TA, Elmore M, Herbert M, McLeod A, Bokori-Brown M, Ostrowski A, Minton NP.** 2002. Conjugative transfer of clostridial shuttle vectors from *Escherichia coli* to *Clostridium difficile* through circumvention of the restriction barrier. *Mol Microbiol* **46**: 439-52
196. **Hussain HA, Roberts AP, Mullany P.** 2005. Generation of an erythromycin-sensitive derivative of *Clostridium difficile* strain 630 (630 Δ erm) and demonstration that the conjugative transposon Tn916 Δ E enters the genome of this strain at multiple sites. *J Med Microbiol* **54**: 137-41
197. **Wilson KH.** 1983. Efficiency of various bile salt preparations for stimulation of *Clostridium difficile* spore germination. *J Clin Microbiol* **18**: 1017-9
198. **Sloan J, Warner TA, Scott PT, Bannam TL, Berryman DI, Rood JL.** 1992. Construction of a sequenced *Clostridium perfringens*-*Escherichia coli* shuttle plasmid. *Plasmid* **27**: 207-19
199. **Blatny JM, Brautaset T, Winther-Larsen HC, Karunakaran P, Valla S.** 1997. Improved broad-host-range RK2 vectors useful for high and low regulated gene expression levels in gram-negative bacteria. *Plasmid* **38**: 35-51
200. **Schooley DL, Kubiak FM, Evans JV.** 1985. Capillary gas chromatographic analysis of volatile and non-volatile organic acids from biological samples as the t-butyltrimethylsilyl derivatives. *J Chromatogr Sci* **23**: 385-90
201. **Li H, Durbin R.** 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**: 1754-60
-

-
202. **Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, Rajandream MA, Barrell B.** 2000. Artemis: sequence visualization and annotation. *Bioinformatics* **16**: 944-5
203. **Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M.** 2006. In-gel digestion for mass spectrometric characterization of proteins and proteomes. *Nat Protoc* **1**: 2856-60
204. **Boersema PJ, Raijmakers R, Lemeer S, Mohammed S, Heck AJ.** 2009. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. *Nat Protoc* **4**: 484-94
205. **Cox J, Mann M.** 2008. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol* **26**: 1367-72
206. **Dupuy B, Govind R, Antunes A, Matamouros S.** 2008. *Clostridium difficile* toxin synthesis is negatively regulated by TcdC. *J Med Microbiol* **57**: 685-9
207. **Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ.** 2011. *Clostridium difficile* infection in Europe: a hospital-based survey. *Lancet* **377**: 63-73
208. **Hull MW, Beck PL.** 2004. *Clostridium difficile*-associated colitis. *Can Fam Physician* **50**: 1536-40, 43-5
209. **Steele J, Feng H, Parry N, Tzipori S.** 2010. Piglet models of acute or chronic *Clostridium difficile* illness. *J Infect Dis* **201**: 428-34
210. **Rothman SW.** 1981. Presence of *Clostridium difficile* toxin in guinea pigs with penicillin-associated colitis. *Med Microbiol Immunol* **169**: 187-96
211. **Kelly CP, Becker S, Linevsky JK, Joshi MA, O'Keane JC, Dickey BF, LaMont JT, Pothoulakis C.** 1994. Neutrophil recruitment in *Clostridium difficile* toxin A enteritis in the rabbit. *J Clin Invest* **93**: 1257-65
212. **Goulding D, Thompson H, Emerson J, Fairweather NF, Dougan G, Douce GR.** 2009. Distinctive profiles of infection and pathology in hamsters infected with *Clostridium difficile* strains 630 and B1. *Infect Immun* **77**: 5478-85
213. **Douce G, Goulding D.** 2010. Refinement of the hamster model of *Clostridium difficile* disease. *Methods Mol Biol* **646**: 215-27
-

-
214. **Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP.** 2008. A mouse model of *Clostridium difficile*-associated disease. *Gastroenterology* **135**: 1984-92
215. **Keel MK, Songer JG.** 2006. The comparative pathology of *Clostridium difficile*-associated disease. *Vet Pathol* **43**: 225-40
216. **Huang IH, Sarker MR.** 2006. Complementation of a *Clostridium perfringens spo0A* mutant with wild-type *spo0A* from other *Clostridium* species. *Appl Environ Microbiol* **72**: 6388-93
217. **Lereclus D, Agaisse H, Grandvalet C, Salamitou S, Gominet M.** 2000. Regulation of toxin and virulence gene transcription in *Bacillus thuringiensis*. *Int J Med Microbiol* **290**: 295-9
218. **Saile E, Koehler TM.** 2002. Control of anthrax toxin gene expression by the transition state regulator *abrB*. *J Bacteriol* **184**: 370-80
219. **Vohra P, Poxton IR.** 2011. Comparison of toxin and spore production in clinically relevant strains of *Clostridium difficile*. *Microbiology* **157**: 1343-53
220. **Onderdonk AB, Cisneros RL, Bartlett JG.** 1980. *Clostridium difficile* in gnotobiotic mice. *Infect Immun* **28**: 277-82
221. **Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, Donskey CJ.** 2007. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic *Clostridium difficile* strains among long-term care facility residents. *Clin Infect Dis* **45**: 992-8
222. **Lell B, Kremsner PG.** 2002. Clindamycin as an antimalarial drug: review of clinical trials. *Antimicrob Agents Chemother* **46**: 2315-20
223. **Croucher NJ, Fookes MC, Perkins TT, Turner DJ, Marguerat SB, Keane T, Quail MA, He M, Assefa S, Bahler J, Kingsley RA, Parkhill J, Bentley SD, Dougan G, Thomson NR.** 2009. A simple method for directional transcriptome sequencing using Illumina technology. *Nucleic Acids Res* **37**: e148
224. **Hegde PS, White IR, Debouck C.** 2003. Interplay of transcriptomics and proteomics. *Curr Opin Biotechnol* **14**: 647-51
-

-
225. **Wasinger V.** 2006. Holistic biology of microorganisms: genomics, transcriptomics, and proteomics. *Methods Biochem Anal* **49**: 3-14
226. **Fujita M, Gonzalez-Pastor JE, Losick R.** 2005. High- and low-threshold genes in the Spo0A regulon of *Bacillus subtilis*. *J Bacteriol* **187**: 1357-68
227. **Hundsberger T, Braun V, Weidmann M, Leukel P, Sauerborn M, von Eichel-Streiber C.** 1997. Transcription analysis of the genes *tcdA-E* of the pathogenicity locus of *Clostridium difficile*. *Eur J Biochem* **244**: 735-42
228. **Andreesen JR.** 1994. Glycine metabolism in anaerobes. *Antonie Van Leeuwenhoek* **66**: 223-37
229. **Sebaihia M, Peck MW, Minton NP, Thomson NR, Holden MT, Mitchell WJ, Carter AT, Bentley SD, Mason DR, Crossman L, Paul CJ, Ivens A, Wells-Bennik MH, Davis IJ, Cerdeno-Tarraga AM, Churcher C, Quail MA, Chillingworth T, Feltwell T, Fraser A, Goodhead I, Hance Z, Jagels K, Larke N, Maddison M, Moule S, Mungall K, Norbertczak H, Rabinowitsch E, Sanders M, Simmonds M, White B, Whithead S, Parkhill J.** 2007. Genome sequence of a proteolytic (Group I) *Clostridium botulinum* strain Hall A and comparative analysis of the clostridial genomes. *Genome Res* **17**: 1082-92
230. **Fonknechten N, Chaussonnerie S, Tricot S, Lajus A, Andreesen JR, Perchat N, Pelletier E, Gouyvenoux M, Barbe V, Salanoubat M, Le Paslier D, Weissenbach J, Cohen GN, Kreimeyer A.** 2010. *Clostridium sticklandii*, a specialist in amino acid degradation: revisiting its metabolism through its genome sequence. *BMC Genomics* **11**: 555
231. **Dickert S, Pierik AJ, Buckel W.** 2002. Molecular characterization of phenyllactate dehydratase and its initiator from *Clostridium sporogenes*. *Mol Microbiol* **44**: 49-60
232. **Herrmann G, Jayamani E, Mai G, Buckel W.** 2008. Energy conservation via electron-transferring flavoprotein in anaerobic bacteria. *J Bacteriol* **190**: 784-91
233. **Tannler S, Decasper S, Sauer U.** 2008. Maintenance metabolism and carbon fluxes in *Bacillus* species. *Microb Cell Fact* **7**: 19
234. **Lie TJ, Pitta T, Leadbetter ER, Godchaux W, 3rd, Leadbetter JR.** 1996. Sulfonates: novel electron acceptors in anaerobic respiration. *Arch Microbiol* **166**: 204-10
-

-
235. **Romano AH, Eberhard SJ, Dingle SL, McDowell TD.** 1970. Distribution of the phosphoenolpyruvate: glucose phosphotransferase system in bacteria. *J Bacteriol* **104**: 808-13
236. **Beyer A, Hollunder J, Nasheuer HP, Wilhelm T.** 2004. Post-transcriptional expression regulation in the yeast *Saccharomyces cerevisiae* on a genomic scale. *Mol Cell Proteomics* **3**: 1083-92
237. **Franklund CV, de Prada P, Hylemon PB.** 1990. Purification and characterization of a microbial, NADP-dependent bile acid 7- α -hydroxysteroid dehydrogenase. *J Biol Chem* **265**: 9842-9
238. **Coleman JP, Hudson LL, Adams MJ.** 1994. Characterization and regulation of the NADP-linked 7- α -hydroxysteroid dehydrogenase gene from *Clostridium sordellii*. *J Bacteriol* **176**: 4865-74
239. **Topping DL, Clifton PM.** 2001. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. *Physiol Rev* **81**: 1031-64
240. **Sakuragi H, Kuroda K, Ueda M.** 2011. Molecular breeding of advanced microorganisms for biofuel production. *J Biomed Biotechnol* **2011**: 416931
241. **Cai G, Jin B, Saint C, Monis P.** 2011. Genetic manipulation of butyrate formation pathways in *Clostridium butyricum*. *J Biotechnol* **155**: 269-74
242. **Emeruwa AC, Hawirko RZ, Halvorson H, Suzuki I.** 1974. Comparison of butyric type of fermentation in sporogenic and asporogenic mutants of *Clostridium botulinum*. *J Bacteriol* **120**: 74-80
243. **Nickerson KW, Bulla LA.** 1980. Incorporation of Specific Fatty Acid Precursors During Spore Germination and Outgrowth in *Bacillus thuringiensis*. *Appl Environ Microbiol* **40**: 166-8
244. **Alsaker KV, Spitzer TR, Papoutsakis ET.** 2004. Transcriptional analysis of spo0A overexpression in *Clostridium acetobutylicum* and its effect on the cell's response to butanol stress. *J Bacteriol* **186**: 1959-71
245. **Twine SM, Reid CW, Aubry A, McMullin DR, Fulton KM, Austin J, Logan SM.** 2009. Motility and flagellar glycosylation in *Clostridium difficile*. *J Bacteriol* **191**: 7050-62
-

-
246. **Richardson K.** 1991. Roles of motility and flagellar structure in pathogenicity of *Vibrio cholerae*: analysis of motility mutants in three animal models. *Infect Immun* **59**: 2727-36
247. **Yao R, Burr DH, Doig P, Trust TJ, Niu H, Guerry P.** 1994. Isolation of motile and non-motile insertional mutants of *Campylobacter jejuni*: the role of motility in adherence and invasion of eukaryotic cells. *Mol Microbiol* **14**: 883-93
248. **Eaton KA, Morgan DR, Krakowka S.** 1992. Motility as a factor in the colonisation of gnotobiotic piglets by *Helicobacter pylori*. *J Med Microbiol* **37**: 123-7
249. **Piggot PJ, Hilbert DW.** 2004. Sporulation of *Bacillus subtilis*. *Curr Opin Microbiol* **7**: 579-86
250. **Tsou AM, Frey EM, Hsiao A, Liu Z, Zhu J.** 2008. Coordinated regulation of virulence by quorum sensing and motility pathways during the initial stages of *Vibrio cholerae* infection. *Commun Integr Biol* **1**: 42-4
251. **Syed KA, Beyhan S, Correa N, Queen J, Liu J, Peng F, Satchell KJ, Yildiz F, Klose KE.** 2009. The *Vibrio cholerae* flagellar regulatory hierarchy controls expression of virulence factors. *J Bacteriol* **191**: 6555-70
252. **Ramos HC, Rumbo M, Sirard JC.** 2004. Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa. *Trends Microbiol* **12**: 509-17
253. **Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL, Wilson IA.** 2012. Structural basis of TLR5-flagellin recognition and signaling. *Science* **335**: 859-64
254. **Segain JP, Raingeard de la Bletiere D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottiere HM, Galmiche JP.** 2000. Butyrate inhibits inflammatory responses through NF κ B inhibition: implications for Crohn's disease. *Gut* **47**: 397-403
255. **Meijer K, de Vos P, Priebe MG.** 2010. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health? *Curr Opin Clin Nutr Metab Care* **13**: 715-21
-

256. **Sun N, Pan C, Nickell S, Mann M, Baumeister W, Nagy I.** 2010. Quantitative proteome and transcriptome analysis of the archaeon *Thermoplasma acidophilum* cultured under aerobic and anaerobic conditions. *J Proteome Res* 9: 4839-50
257. **Dressaire C, Gitton C, Loubiere P, Monnet V, Queinnec I, Cocaign-Bousquet M.** 2009. Transcriptome and proteome exploration to model translation efficiency and protein stability in *Lactococcus lactis*. *PLoS Comput Biol* 12: e1000606